Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial (Q30440147)

14 August 2017

Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial (English)

1 reference

14 August 2017

0 references

placebo-controlled trial

1 reference

1 reference

1 reference

4

Bruce E Sands

1 reference

14 August 2017

5

Stephen B Hanauer

1 reference

14 August 2017

2

Gary R Lichtenstein

1 reference

14 August 2017

1

James D Lewis

1 reference

14 August 2017

Julius J Deren

3

1 reference

14 August 2017

Jeffrey A Katz

6

1 reference

14 August 2017

Bret Lashner

7

1 reference

14 August 2017

Daniel H Present

8

1 reference

14 August 2017

Shaokun Chuai

9

1 reference

14 August 2017

Jonas H Ellenberg

10

1 reference

14 August 2017

Lisa Nessel

11

1 reference

14 August 2017

Gary D Wu

12

1 reference

14 August 2017

Rosiglitazone for Ulcerative Colitis Study Group

13

1 reference

14 August 2017

language of work or name

English

0 references

publication date

7 December 2007

1 reference

14 August 2017

1 reference

14 August 2017

134

1 reference

14 August 2017

3

1 reference

14 August 2017

688-695

1 reference

Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

Safety issues and prospects for future generations of PPAR modulators

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

Cancer risks in thiazolidinedione users compared to other anti-diabetic agents

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

Expression of peroxisome proliferator-activated receptor-gamma in macrophage suppresses experimentally induced colitis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

PPARgamma as a new therapeutic target in inflammatory bowel diseases

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

Role of PPARgamma in macrophage biology and atherosclerosis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

The risk of colorectal cancer in ulcerative colitis: a meta-analysis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

The organization, promoter analysis, and expression of the human PPARgamma gene

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

Quantification of the placebo response in ulcerative colitis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

The nuclear receptor superfamily: the second decade

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

The impact of confounder selection criteria on effect estimation

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2276587

Inflammatory bowel disease and the risk of fracture

26 November 2018

1 reference

12 December 2020

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study

1 reference

12 December 2020

Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?

1 reference

12 December 2020

Coronary heart disease outcomes in patients receiving antidiabetic agents

1 reference

12 December 2020

Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis

1 reference

12 December 2020

A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes

1 reference

12 December 2020

10.1053/J.GASTRO.2007.12.012

Identifiers

DOI

1 reference

14 August 2017

1 reference

14 August 2017

PubMed publication ID

18325386

1 reference